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ABSTRACT 
The altered gating of the mutant CFTR chloride channel cystic fibrosis (CF) may be corrected by small 
molecules called potentiators. We present a molecular scale simulation system for the discovery of 
F508-CFTR soluble potentiators. Results report the design, ADME-Tox prediction, synthesis, 
solubility determination and in vitro biological evaluation of two 1,4-dihydropyridines (DHPs). 
Compound 1 shows a promising ADME-Tox profile and good potency.  
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Introduction 
Cystic fibrosis (CF), a serious disease afflicting about 1 in 2500 individuals in the Caucasian 
population, is caused by inherited mutations in the CF transmembrane conductance regulator (CFTR) 
gene [1]. The product of this gene is a plasma membrane protein with Cl-channel function [2]. The most 
common disease-causing mutation of CFTR is F508, a deletion of phenylalanine at position 508 [3]. 
∆F508 impairs the maturation of as well the gating of CFTR protein. Instead, other mutations such as 
G551D and G1349D cause only a gating defect. 
Small-molecule therapy for CF-causing mutations is thought to have considerable promise [4] but to 
the best of our knowledge only one structure-based virtual screening strategy [5] and no ligand-based 
approach for the discovery of new CFTR modulators is reported in the literature (some QSAR and SAR 
studies were performed a posteriori after synthesis and biological testing of compounds [6-9]). 
Ligand-based design methods capitalize on the fact that ligands similar to an active ligand are more 
likely to be active than random ligands. This approach could be extremely useful for CFTR potentiators 
because the lack of a high resolution 3D structure of the full length protein prevents a clear strategy for 
designing compounds that act by direct interaction with CFTR to be defined [5]). 
1,4-dihydropyridines (DHPs) used to treat hypertension also act as CFTR potentiators, i.e. 
pharmacological compounds restoring the activity of CFTR mutants with defective gating [10]. As 
antihypertensive agents, DHPs act by blocking L-type voltage-dependent Ca2+ channels (L-VDCC) and 
therefore cause the relaxation of arterial smooth muscle cells [11]. It was also found that mutant CFTR 
is activated by DHPs through a mechanism not involving the modulation of Ca2+ channels, but by a 
probable direct interaction with the CFTR protein itself [11]. 
DHP is considered a privileged scaffold by medicinal chemists since a large amount of information is 
available on pharmacokinetics and toxicity properties and its chemical accessibility could enable, in 
case of success, a rapid start of clinical trials [12]. However, the ability of DHPs to interact with a 
number of pharmacological targets is also the source of selectivity issues [12]. 
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Pedemonte et al. in 2007 [6] identified four DHPs of potential interest (DHP106, DHP194, DHP229 
and DHP256, Figure 1) since endowed with a potency as CFTR potentiators higher than that as Ca2+ 
channel blockers, the opposite of what is found for anti-hypertensive DHPs such as felodipine.  
However, the novel DHPs are expected to be poorly soluble in water (see below). 
Figure 1 
This study firstly describes a molecular scale simulation system to check the feasibility of discovering 
new soluble CFTR potentiators based on the DHP scaffold. Then the two molecules of potential interest 
resulting from the in silico studies were synthesized, submitted to aqueous solubility measurements and 
tested as CFTR activators with a functional assay (methods for evaluating direct binding to the full 
length CFTR or its F508 mutant are currently unavailable) based on the measurement of CFTR-
mediated anion transport. 
Results and discussion 
The whole design procedure consisted in five steps: a) building and interpretation of a robust 
3D-QSAR model for a series of 105 DHPs active as CFTR potentiators; b) set-up of a 3D-QSAR model 
able to predict Ca2+ channel blockade; c) in silico solubility analysis; d) design of new structures on the 
basis of the information arising from the previous steps and e) check of the two candidates for their 
ADME-Tox and solubility profiles. 
3D-QSAR model of DHPs as CFTR activators 
From the dataset of felodipine analogues discussed by Pedemonte et al. [6], the molecules with 
numerical (we selected to include in the dataset only the molecules that have numerical measured values 
of biological activity and we decided not to include the molecules that have only "text " values, e.g - 
"higher than”) Kd values as CFTR activators were selected (105) and then split in a training (66) and a 
test set (37).  
Among the plethora of descriptors today available to build 3D-QSAR models, we decided to use 
Molecular Interaction Fields [13, 14] based descriptors, i.e. the GRID Independent Descriptors 
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(GRIND) [15, 16] because they were successfully used in many cases to model pharmacodynamics 
activities [17, 18]. After building the 3D structures, GRIND descriptors were calculated both for the 
training and the test set using Pentacle as software (see Experimental Part). 
According to the OECD principles of QSAR validation [19] as an essential requirement for QSAR 
studies, the GRIND-based 3D-QSAR model was built. To do that, the Kd values (dF508-CFTR, M) 
were transformed in pKd (the larger the more potent) and related to GRIND descriptors by a PLS 
algorithm. Statistical results are in Table 1 and prove that a robust model was found.  
Table 1 
The test set prediction was convincing: SDEP is 0.34 and values close to 1 for the slope and close to 0 
for the Y-intercept in the linear regression relating experimental and calculated values were calculated 
(Figure 2). For three compounds (DHP008, DHP054 and DHP183) the difference between experimental 
and calculated values is larger than one logarithmic unit. This discrepancy could not be attributed to the 
presence of a nitro group in meta and para position on the DHP aromatic ring (present both in DHP008 
and DHP054) since this feature is also present in structures whose pKd is well predicted. The bad 
prediction of DHP183 could be due to the peculiar aromatic substitutions.  
Figure 2 
The CFTR activator model was submitted to chemical interpretation as discussed below. Figure 3 
shows the most relevant GRIND for three compounds: two good CFTR potentiators, DHP194 and 
DHP242, and one with poor biological activity, DHP138 (distances in red are favorable, i.e distances 
that increase biological activity, whereas distances in blue are not favorable i.e distances that decrease 
biological activity). Of particular relevance in DHP194 the unfavorable (blue) distance between red (due 
to the O probe) and green (due to the TIP probe) crosses (d1 in Figure 3) that indicates that the regions 
defining the corresponding spatial extents probably do not fit well into the receptor binding pockets, i.e. 
steric hindrance. A second unfavorable (blue) distance related to steric limits is d2 in Figure 3. This 
distance suggests that to obtain good CFTR potentiators it is preferable to avoid large substituents in 2 
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and 6. 
Figure 3 
3D-QSAR model of DHPs as calcium channel blockers 
Here binary values (see Experimental Part) were related to the GRIND descriptors by a PLS 
algorithm. Results are in Table 1 and show that also for the Ca2+ channel blocking activity a good 
statistical model was found. The five compounds badly predicted (three false positives and two false 
negatives, see Experimental Part) were close to the threshold value selected to distinguish very active 
from less active compounds.  
Once statistically validated, we verified that the model caught most of the structural features 
important for Ca2+-channel-blocking activity reported in the literature [12]. As an example, an 
unsubstituted NH group (R1 = H) in the DHP ring is important for the blocking action. This is shown in 
Fig. 4 for DHP 147 (binary value = -1) for which a number of unfavorable distances (blue) are located 
close to the methylated DHP nitrogen. The rules for Ca2+-channel-blocking activity associated to the 
substitution at the phenyl ring at R4 are also verified by our model. The requirements of a substituent at 
the phenyl group for optimal activity include: a) a bulky substituent at the ortho position; b) a bulky but 
not lengthy substituent at the meta-position and c) a small substituent at the para-position. This is shown 
in Fig. 3 for DHP184 (binary value = -1) that exhibits a large substituent in para position connected by 
an unfavourable (blue) distance to the hydrophobic region of the DHP. The ester substituents at R3 and 
R5 and substituents at R2 and R6 that greatly influence the potency and selectivity of the DHP’s are also 
retrieved by the model (data not shown). 
Figure 4 
Solubility analysis 
The aqueous solubility at pH = 7.5 was calculated using the model implemented in VolSurf+ [20]. 
Results (Figure 5) evidenced that most of the active compounds of the original dataset (also the four 
most promising in Figure 1) could present solubility problems in vivo since they are largely less soluble 
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than nifedipine (-3.72).  
Figure 5 
Design 
The main aim of the design step was to maximize potency, selectivity and aqueous solubility of 
molecules bearing the DHP scaffold. To do that we firstly focused on obtaining structures active as 
CFTR potentiators. According to Fig. 3 guidelines, we firstly selected a DHP scaffold bearing methyl 
groups in position 3 and 5 and a phenyl ring meta substituted with a nitro group in position 4.  
To improve solubility we decided to introduce a polar moiety and in particular a nitrooxyl group since 
a) some DHPs bearing a nitrate are already described in the literature (see above) [21, 22] b) among 
polar groups OHs are detrimental for CFTR potency [6] and c) a basic amino group was discarded 
because it could be related to diffusion-limited rate issues [23]. 
The calcium channel blocking activity was not specifically minimized but any proposed structure with 
expected good CFTR potency and solubility was checked for its Ca2+ channel antagonism by the aid of 
the QSAR model described above. 
Compound 1 in Figure 6 was finally proposed as a compound with a promising medicinal chemistry 
profile (calculated pKd : 5.89) whereas 2 (calculated pKd : 5.47) was individuated as a compound of 
interest to validate the molecular scale simulation system. 
Figure 6 
Compounds 1 and 2 were then submitted to calculations to obtain ADME-Tox and physicochemical 
descriptors (Table S3). In particular the molecules were projected on the following pre-calculated 
models implemented in VolSurf+ [20]: aqueous solubility at pH = 7.5 and log P, Caco-2 cell 
permeability, plasma protein affinity, blood–brain barrier permeation and metabolic stability. The 
models are based on VolSurf+ descriptors that in turn are obtained from MIFs by calculating the volume 
or the surface of the interaction contours at predefined energy values [20].  
The ADME-Tox profiles of drug-likeness 1 and 2 were evaluated according to the rules proposed by 
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Carosati et al. [24]. Nifedipine data were calculated and reported as a comparison. The 
physico-chemical and pharmacokinetic descriptors (Table 2) were fully convincing since all values are 
in line with alert threshold values [24]. According to solubility predictions, 1 shows a better profile than 
molecules present in the original dataset whereas 2 could be ranked in an intermediate position 
(Figure 5).  
Finally, hERG toxicity was predicted on the basis of a QSAR model recently published by some of us 
[25] by using the threshold value of 6 (pIC50 units) to distinguish active (i.e. potentially toxic) from not 
active compounds [26]. Results indicate that some concerns could arise for 2 since the predicted hERG 
toxicity value is larger (6.20) than suggested threshold value (6.0, see above). 
Table 2 
Chemistry 
The procedure to obtain 1 is described in the literature [21] The racemic compound (±) 2 was 
prepared by synthetic route as depicted in Scheme 1, which involved use of a modification of Hantzsch 
reaction. 3-Nitrooxypropyl-3-amino-2-butenoate c [23] was condensed with 3-nitrobenzaldehyde a and 
nitroacetone b to afford a racemic mixture of 2. 
Scheme 1  
Physicochemical and biological evaluation 
Experimental solubility of nifedipine, 1 and 2 was then determined at pH 7.4 in phosphate buffer and 
the following data in –lgS 7.5 (mg/L) were found: 1 -4.88 (5.3 ± 0.3), 2 -4.88 (5.8 ± 1.2), and nifedipine 
-4.18 (22.6 ± 12.2). Compounds 1 and 2 are thus slightly less soluble than nifedipine but more soluble 
than most compounds of the investigated dataset. These data also show some limits in the VolSurf+ 
predictions. 
Bearing a nitrooxyl group, the final DHPs 1 and 2 were assessed for their ability to generate NO in the 
presence of a large excess of cysteine (1:50) in buffer solution (pH 7.4) at 37 °C. The extent of NO 
production after 1 h was determined by detection of nitrite, which is the oxidative metabolite of nitric 
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oxide (Griess reaction). Results show that in these experimental conditions neither 1 nor 2 are able to 
release nitric oxide (< 0.5 % NO2
-). 
We then determined dose–response relationships for 1 and 2 as ∆F508-CFTR potentiators. For this 
purpose, we utilized the functional assay based on the halide-sensitive yellow fluorescent protein, HS-
YFP [11]. Cells are first incubated at low temperature to rescue the mutant protein from the 
endoplasmic reticulum allowing its targeting to the plasma membrane. Then cells are acutely stimulated 
with a high concentration of the adenylyl cyclase inhibitor forskolin, to allow maximal ∆F508-CFTR 
phosphorylation, in the absence or presence of test compounds. ∆F508-CFTR activity is measured as the 
rate in HS-YFP fluorescence quenching caused by iodide influx, as previously described [11]. True 
potentiators increase activity above the level obtained with forskolin alone. This was the case for 
compounds 1 and 2. Fitting of data obtained at different concentrations with a Hill equation allowed to 
estimate apparent Kd and maximal effect. The following Kd values were determined: 1.3 M for 1 and 
3.4 M for 2 (corresponding pKd values, 5.88 and 5.07, respectively), in good agreement with 
calculated values (5.89 and 5.47). Maximal effect of these compounds was comparable to that of the 
most effective DHPs previously tested [11].  
Summing-up the new strategy here proposed enabled to discover 1 as a CFTR potentiator of potential 
interest and to highlight the limits of 2. Moreover, results also showed that the insertion of a nitrooxyl 
group on the 1-4-DHP supports CFTR potency.  
Conclusions 
Effective CFTR potentiators are very useful for the treatment of CF patients affected by mutations 
that cause impaired CFTR channel gating. Among the various families of chemical compounds showing 
potentiator activity, DHPs are particularly interesting because of existing information on medicinal 
chemistry and pharmacological properties.  
Our study presents a new ligand-based strategy to discover novel DHPs potentiators with improved 
drug-like characteristics. In particular here for the first time a 3D-QSAR model able to predict the 
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CFTR activation properties is described and experimentally validated. Since this model is combined 
with computational strategies to predict calcium channel blocking activity and ADME-Tox filtering 
procedures, the study as a whole sounds very promising in the development of strategies to discover 
drug candidates for CF therapy.  
Nevertheless the solid design procedure is necessary but not sufficient to discover highly potent, 
selective and soluble CFTR potentiators based on the DHP scaffold since solubility seems to negatively 
affect CFTR potentiators potency. This could be related to some hydrophobic features of the receptor 
responsible for CFTR activity. This point could be clarified on the basis of a high-resolution 3D 
structure of CFTR in complex with one validated activator currently unavailable. 
Experimental Part 
Molecular modeling 
To build the 105 structures two automatic builders (Frog 2.1 (http://bioserv.rpbs.univ-paris-
diderot.fr/cgi-bin/Frog2) and MOE) were used and two datasets (called Frog_ds and MOE_ds, 
respectively) were prepared. Since only a modest stereoselectivity was observed in previous studies for 
niguldipine, BayK-8644 and isradipine [11], the stereochemistry proposed by the automatic tools was 
maintained (R for MOE and S for Frog). Frog_ds and MOE_ds were submitted to AM1 minimization 
which yelded Frog_ds_min and MOE_ds_min, respectively. Four datasets were thus built to check the 
dependence of the models on the adopted 3D building strategy. This approach was chosen both on the 
basis of a previous work [27] and also to take into account the controversial reports in the literature 
about DHPs structural features: DHP of the nifedipine type are flexible molecules, in which the C-4-aryl 
moiety and the C-3 and C-5 ester substituents can rotate and the conformation of the DHP ring can 
change [12]. Preliminary tests (data not reported) showed that the best models are found by using the 3D 
structures arising from Frog builder and minimized with AM1 semi empirical method. All remaining 
models based on different training sets were of slightly lower quality and their chemical interpretation 
did not significantly differ from the one reported below.  
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The final structures were saved in mol2 format, randomly split in training (66) and test sets (39) and 
submitted to Pentacle (version 1.0.5, Molecular Discovery Ltd. Pinner, Middlesex, UK, 2010, 
http://www.moldiscovery.com), and VolSurf+ (version 1.0.4, Molecular Discovery Ltd. Pinner, 
Middlesex, UK, 2009, http://www.moldiscovery.com). 
A standard procedure to build 3D-QSAR models already described by some of us [27] was used in 
Pentacle. Briefly, four probes (DRY, O, N1 and TIP) and default values for all Pentacle parameters were 
used; MIFs filtering and encoding tools were combined to produce four sets of GRIND descriptors: 
ALMOND/MACC2, ALMOND/CLACC, AMANDA/MACC2 and AMANDA/CLACC. We built 
models with the four sets and selected the model with the best statistical performance 
(AMANDA/CLACC for both models). Since the L-VDCC inhibition percentage at 1 M reported in the 
original paper [6] is not an appropriate biological endpoint because of the nonlinear characteristic of 
dose/response relationships, for the calcium channel blocking model we decided to adopt a simple 
binary classification of data [18]. Compounds with the L-VDCC inhibition percentage larger than 80% 
were set as active (value=1) whereas compounds with this percentage smaller or equal to 80% were set 
inactive (value=-1). This classification is arbitrary but it takes into account the high-throughput format 
of the data and their distribution (see Supporting Information). In our opinion it is acceptable to build a 
fast screening model to use as a support in a more complex design program. 
The 3D structures were submitted to VolSurf+ using default settings and four probes (OH2, DRY N1 
and O probes that mimic respectively water, hydrophobic, hydrogen bond acceptor and hydrogen bond 
donor interaction of the compounds with the environment) [18, 20]. The molecules were projected on 
the pre-calculated models implemented in VolSurf+ to calculate ADME-Tox parameters and solubility. 
PCA and PLS tools implemented in Pentacle were used. In addition XLStat v.2009.6.04 
(www.xlstat.com) was also used to obtain the VIP plots. 
All calculations were performed on a Linux based server and on standard PCs operating with 
Microsoft Windows 7. 
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Chemistry 
Melting points were determined on a Büchi 530 apparatus after introducing the sample into the bath at 
a temperature 10 °C lower than the melting point. A heating rate of 1 °C min-1 was used, 3 °C min-1 in 
the case of decomposition. The compounds were routinely checked by infrared spectrophotometry 
(Shimadzu FT-IR 8101). 1H and 13C NMR spectra were recorded on a Bruker AC-200 spectrometer and 
are reported in ppm units (* means either not assigned or tentatively assigned). All of the spectra were 
in keeping with the structures. Column chromatography was performed on silica gel (Merck Kieselgel 
60, 230-400 mesh ASTM) with the indicated solvent system. Anhydrous MgSO4 was used as a drying 
agent. Solvent removal was achieved under reduced pressure at room temperature. Elemental analyses 
of the new compound was performed by REDOX (Cologno Monzese), and the result is within 0.4% of 
the theoretical values.  
Synthesis of ()3-Nitrooxypropyl 1,4-Dihydro-2,6-dimethyl-5-nitro-4-(3-nitrophenyl)pyridine-3-
carboxylate (compound 2): A mixture of 3-nitrobenzaldehyde (0.73 g, 5 mmol) and nitroacetone  (1.8 
g, 17.5 mmol) in 2-propanol (40 mL) was refluxed for 4h. 3-Nitrooxypropyl-3-amino-2-butenoate (1.08 
g, 5 mmol) was added and heating was continued for other 4 h; solvent removal gave a residue which 
was purified by flash-chromatography (petroleum ether 6 / ethyl acetate 4). The yellow solid was 
recrystallized from CHCl3/PE. Yield 30%; mp154°C. 
1H-NMR (DMSO-d6): 1.967 (q, 2H, CCH2C); 2.34 (s, 3H, 6-CH3); 2.52 (s, 3H, 2-CH3); 4.08 (t, 2H, 
CH2ONO2); 4.42 (t, 2H, OCH2); 5.36 (s, 1H, 4-CH); 7.54-8.07 (m, 4H, Ph); 9.79 (s br, 1H, NH).  
13C-NMR (DMSO-d6): 17.95 (2-CH3); 19.67 (6-CH3); 25.68 (CCH2C); 39.60 (C4-DHP); 60.56 (OCH2); 
70.85 (CH2ONO2); 105. 24 (C5-DHP); 125.75 (C3-DHP); 121.92 , 122.25, 129.90, 134.53, 145.31*, 
147.09*(Ph); 147.85*, 148.17* (C2,C6-DHP); 165.82 (COO) (*tentatively assigned). 
Cell culture 
Fischer rat thyroid (FRT) cells with stable co-expression of F508-CFTR and the halide-sensitive 
yellow fluorescent protein YFP-H148Q/I152L [11] were cultured at 37 °C (5% CO2 atmosphere) in 
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Coon’s modified Ham’s F-12 medium plus 10% fetal calf serum, 2 mM L-glutamine, 100 U/ml 
penicillin, and 100 µg/ml streptomycin. Zeocin (0.6 mg/ml) and G418 (0.75 mg/ml) were also included 
in the medium to maintain selection for mutant CFTR and the fluorescent protein expression, 
respectively. For the functional assay performed with a microplate reader, cells were plated in black-
wall clear-bottom 96-well microplates (Corning 3603) at a density of 50,000 cells per well. After 24 
hours from plating, cells were incubated for further 20-24 hours at 27 °C to rescue F508-CFTR to the 
cell surface [11].  
Fluorescence assay for CFTR activity 
Cells were washed with PBS (containing 137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4, 1.5 mM 
KH2PO4, 1 mM CaCl2 and 0.5 mM MgCl2) and stimulated for 30 min with forskolin (20 µM) with or 
without test compounds at different concentrations. The cells were then transferred to a microplate 
reader (FluoStar Galaxy; BMG Labtech GmbH, Offenburg, Germany) for CFTR activity determination. 
The plate reader was equipped with high-quality excitation (ET500/20X: 500 ± 10 nm) and emission 
(ET535/30M: 535 ± 15 nm) filters for YFP (Chroma Technology Corp., Brattleboro, VT). Each assay 
consisted of a continuous 14-s fluorescence reading with 2 s before and 12 s after injection of an iodide-
containing solution (PBS with Cl- replaced by I-; final I- concentration in the well: 100 mM). Data were 
normalized to the initial background-subtracted fluorescence. To determine fluorescence quenching rate 
(QR) associated with I- influx, the final 11 s of the data for each well were fitted with an exponential 
function to extrapolate initial slope (dF/dt). 
Solubility 
The solubility was evaluated introducing an excess of analyte (nifedipine, compounds 1, 2) in a 
volumetric flask in concentrated (10 mg/mL) methanolic solution and allowing it to evaporate before the 
addition of the solvent buffer (50 mM phosphate buffer, pH 7.4). 
The concentration of the supernatant solution was determined after 30 minutes of solubilization 
treatment in a ultrasound bath at room temperature by HPLC-UV-MS using a Dionex Ultimate 3000 
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chromatographic system, (Dionex, Milan, Italy) equipped with two detectors: Surveyor DAD detector 
and LTQ-Orbitrap (Thermo Scientific, Rodano, Italy) spectrometer, with electrospray interface and ion 
trap as high resolving power mass analyzer. The chromatographic separations were run on a 
Phenomenex Luna C18 column (150  2 mm, 3 µm particle size) (Phenomenex, Torrance, CA, USA). 
Flow rate was 200 μL min-1. Gradient mobile phase composition was adopted: 70/30 to 100/0 v/v 0.05% 
formic acid in water/methanol in 30 min. Quantitation was done integrating the UV signal (240 nm) 
chromatogram and the identity of the compounds was confirmed by mass spectrometry. Mass spectra 
were collected in tandem MS mode for the following ions 347 (nifedipine), 423 (2) or 436 (1) m/z. The 
retention times of the investigated compounds were 21.0 (nifedipine), 23.2 (2) or 24.4 (1) minutes. 
NO release 
Nitrite production by –ONO2 in the presence of L-cysteine was evaluated according to the procedure 
described in the details elsewhere [28]. A solution of compounds 1 and 2 (20 µL) in DMSO was added 
to 2 mL of 50 mM phosphate buffer  (pH 7.4), containing 5 mM L-cysteine. The final concentration of 
drug was 10-4 M. After 1 h at 37°C, 1 mL of the reaction mixture was treated with 250 µL of the Griess 
reagent (4 g sulfanilamide; 0.2 g N-naphtylethyldiamine dihydrochloride; 10 mL 85% phosphoric acid 
in distilled water. After 10 min at room temperature, absorbance was measured at 540 nm (Perkin-Elmer 
Lambda 5 spectophotometer). 10-880 nmol/mL sodium nitrite standard solution were used for the 
calibration curve. The yield in nitrite was expressed as NO2
- % (mol/mol).  
Supporting Information Available: Experimental and calculated CFTR activation data (pKd) and 
filtered MIFs for 1 and 2, calcium channel blocking 3D-QSAR model details, the whole set of VolSurf+ 
descriptors.  
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Caption to the figures 
Figure 1. Chemical structures of the four DHPs of potential interest proposed by Pedemonte et al. in 
2007 [6]. 
Figure 2. CFTR activators 3D-QSAR model: the linear relationship between the experimental and the 
calculated pKd is shown together with the chemical structure of deviant compounds. 
Figure 3. 3D-QSAR model for CFTR potentiators: filtered MIFs obtained with DRY (yellow), O 
(red). N1 (blue) and TIP (green) probes and the distance ranges corresponding to GRIND with VIPs 
value greater than 1.5. See text for model interpretation. 
Figure 4. Calcium channel blocking 3D-QSAR model: filtered MIFs obtained with DRY (yellow), O 
(red). N1 (blue) and TIP (green) probes and the distance ranges corresponding to GRIND with VIPs 
value greater than 1.5. See text for model interpretation. 
Figure 5. The histogram shows the original dataset solubility predicted by VolSurf+ expressed as 
-lg S 7.5 (the logarithm of solubility [mol/L] computed at pH 7.5, the lower the value, the less soluble 
the compound) together with 1 and 2 data. Compounds are ordered by decreasing potency as CFTR 
activators from the left to the right (the first bar on the left is due to the most potent compound, i.e. 
DHP194).  
Figure 6. Molecules resulting from the in silico procedure. 
Scheme 1. Synthetic procedure to obtain 2. 
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Tables 
Table 1. Statistical results for the best 3D-QSAR models (LVs = Latent Variables, r2 = coefficient of 
determination, q2 = model predictive ability by cross-validation, SDEP = standard deviation error of the 
prediction, precision = tp/(tp+fp) , recall = tp/(tp+fn), accuracy = (tp+tn)/(tp+tn+fp+fn), where tp is the 
number of true positives, tn is the number of true negatives, fp is the number of false positives and fn is 
the number of false negatives [18]). 
CFTR activators Calcium blockers  
Parameter Value Parameter Value 
LVs 4 LVs 3 
r2 0.85 Precision 0.95 
q2 0.50 Recall 1.00 
SDEP 0.34 Accuracy 0.98 
 
Table 2. ADME-Tox profile for hits compared with nifedipine. Values are reported with the threshold 
values discussed elsewhere [24]. 
Descriptor 1 2 Nifedipine Lower 
threshold 
value 
Upper 
threshold 
value 
Log Poct 3.53 2.86 2.45 1 5 
LgS 7.5 -2.77 -2.86 -3.72 -4 Not set 
Absorption 0.22 0.19 0.77 0.2 Not set 
Lg BBB 1.39 1.40 -0.29  0 
Metabolic stability 52.23 60.67 60.03 0.3 Not set 
hERG 1 5.50 6.20 4.11  6.0 (1M) 
1 Calculated by the model reported by Ermondi et al. [25]  
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